Literature DB >> 2127936

Quantitation of didanosine in human plasma and urine by high-performance liquid chromatography.

C A Knupp1, F A Stancato, E A Papp, R H Barbhaiya.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2127936     DOI： 10.1016/s0378-4347(00)82215-x

Source DB:  PubMed          Journal:  J Chromatogr


× No keyword cloud information.
  15 in total

1.  Pharmacokinetic-interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus.

Authors:  C A Knupp; F M Graziano; R M Dixon; R H Barbhaiya
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

2.  Pharmacology and immuno-virologic efficacy of once-a-day HAART in African HIV-infected children: ANRS 12103 phase II trial.

Authors:  Boubacar Nacro; Emmanuelle Zoure; Hervé Hien; Hassane Tamboura; François Rouet; Adama Ouiminga; Ali Drabo; Souleymane Yameogo; Alain Hien; Hélène Peyriere; Olivier Mathieu; Deborah Hirt; Jean-Marc Treluyer; Joëlle Nicolas; Vincent Foulongne; Michel Segondy; Philippe van de Perre; Serge Diagbouga; Philippe Msellati
Journal:  Bull World Health Organ       Date:  2011-04-06       Impact factor: 9.408

3.  Effects of cytokines on antiviral pharmacokinetics: an alternative approach to assessment of drug interactions using bioequivalence guidelines.

Authors:  S C Piscitelli; M A Amatea; S Vogel; C Bechtel; J A Metcalf; J A Kovacs
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

4.  Didanosine measurement by radioimmunoassay.

Authors:  M DeRemer; R D'Ambrosio; G D Morse
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

5.  Pharmacokinetics of co-administered didanosine and stavudine in HIV-seropositive male patients.

Authors:  R D Seifert; M B Stewart; J J Sramek; J Conrad; S Kaul; N R Cutler
Journal:  Br J Clin Pharmacol       Date:  1994-11       Impact factor: 4.335

6.  Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients.

Authors:  K C Cundy; P Barditch-Crovo; R E Walker; A C Collier; D Ebeling; J Toole; H S Jaffe
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

7.  Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients.

Authors:  K C Cundy; B G Petty; J Flaherty; P E Fisher; M A Polis; M Wachsman; P S Lietman; J P Lalezari; M J Hitchcock; H S Jaffe
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

8.  Biopharmaceutics of didanosine in humans and in a model for acid-labile drugs, the pentagastrin-pretreated dog.

Authors:  C A Knupp; W C Shyu; E A Morgenthien; J S Lee; R H Barbhaiya
Journal:  Pharm Res       Date:  1993-08       Impact factor: 4.200

9.  Didanosine pharmacokinetics in patients with normal and impaired renal function: influence of hemodialysis.

Authors:  E Singlas; A M Taburet; F Borsa Lebas; O Parent de Curzon; A Sobel; P Chauveau; B Viron; R al Khayat; J L Poignet; F Mignon
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

10.  Determination of ddATP levels in human immunodeficiency virus-infected patients treated with dideoxyinosine.

Authors:  Cecile Le Saint; Raphael Terreux; Daniele Duval; Jacques Durant; Helene Ettesse; Pierre Dellamonica; Roger Guedj; Jean Pierre Vincent; Anny Cupo
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.